Stephanie M. de Boer

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell et al. · Journal of Clinical Oncology · 2020 · 777 citations · Full text

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2018 · 599 citations · Full text

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2019 · 432 citations · Full text

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin et al. · The Lancet Oncology · 2016 · 176 citations · Full text

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

Lisa Vermij, Jan J. Jobsen, Alicia León‐Castillo et al. · British Journal of Cancer · 2023 · 141 citations · Full text